This document provides a comparison table summarizing various glucose-lowering agents for diabetes, including their effects on A1C and weight, risk of hypoglycemia, cardiovascular outcomes from major trials, and other factors. Metformin has the most favorable profile overall, being low cost and associated with weight loss and fewer side effects. Sulfonylureas, TZDs, and insulin are generally more effective at lowering A1C but carry greater risks of weight gain and hypoglycemia. Incretin mimetics and SGLT2 inhibitors provide additional options for lowering A1C with less hypoglycemia and weight neutral or loss effects, but long-term safety and cardiovascular outcome data remains limited for these newer classes.